Zolmitriptan is an oral, selective 5-hydroxytryptamine 1B/1D (5-HT 1B/1D ) receptor agonist, or triptan, for acute treatment of migraine attacks with or without aura. First launched in 1997, it is one of the second generation of triptan. It is available in tablet form, as a rapidly dissolving tablet that can be taken without water, and as a nasal spray.
People with migraines are often sensitive to artificial sweeteners, and should be aware that Zomg-ZMT (the dissolving tablet) contains aspartame, and hence conatin phenylalanine.
Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Greece & Argentina) and AscoTop (Germany).